May 30, 2026 — RNews

#antibody — Saturday, May 30, 2026 (1 items)

hot top new

← prev day next day →

0

Efficacy and safety of a bodyweight-adjusted higher dose of ocrelizumab in relapsing (MUSETTE) and primary progressive (GAVOTTE) multiple sclerosis: two multicentre, randomised, double-blind, parallel-group phase 3b trials. (linkinghub.elsevier.com)

Hauser SL … Kappos L The Lancet 2026-05-30

#antibody #clinical trial #immunotherapy #multiple sclerosis